Progestin binding in benign hyperplastic prostatic tissue.

D A Sirett

Home/Archive/PubMed

PubMed · 6193339

Progestin binding in benign hyperplastic prostatic tissue.

D A Sirett

View original source ↗Export metadata ↓

Abstract

The identification of saturable binding sites for promegestone (17 alpha, 21-dimethyl-19-norpregna-4,9-diene-3,20-dione) in human prostatic cytosol as progesterone receptors is complicated by some differences in binding behaviour between progesterone and promegestone. These differences seem to result from the presence in cytosol of a second class of progestin-binding sites, which has a higher affinity for progesterone than for promegestone.

Explore related subjects

Binding, Competitive Cytosol Humans Hydrocortisone Kinetics Male Progesterone Promegestone Prostate Prostatic Hyperplasia Receptors, Progesterone Triamcinolone Acetonide Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

D A Sirett. 1983. Progestin binding in benign hyperplastic prostatic tissue.. https://pubmed.ncbi.nlm.nih.gov/6193339/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

Treatment of human monocytes with vascular endothelial growth factor (VEGF) isolated from tumor cell supernatants was reported to induce monocyte activation and migration. In this study we show that recombinant human VEGF165, and VEGF121 had a maximal effect on human monocyte migration at 65 to 250 pmol/L. Chemotactic activity of VEGF165 was inhibited by a specific antiserum against VEGF, by heat treatment of VEGF165, and by protein kinase inhibitors. In addition, we could show that VEGF-stimulated monocyte migration is mediated by a pertussis toxin-sensitive GTP-binding protein. Placenta growth factor (PlGF152), a heparin-binding growth factor related to VEGF, was also chemotactic for monocytes at concentrations between 2.5 and 25 pmol/L. In accordance with these findings, human monocytes showed specific and saturable binding for 125I-VEGF165 (half-maximal binding at 1 to 1.5 nmol/L). Using Northern blot analysis, we further could show that human monocytes express only the gene for the VEGF receptor type, flt-1, but not for the second known VEGF receptor, KDR. Resting monocytes expressed low levels of flt-1 gene only. Brief exposure (2 to 4 hours) of human monocytes to lipopolysaccharide, a prototypic monocyte activator, led to a significant upregulation of the flt-1 mRNA level. The results presented here suggest that monocyte chemotaxis in response to VEGF and most likely to PlGF152 is mediated by flt-1 and thus show a possible function for the VEGF-receptor flt-1.

Binding, Competitive↗

PubMed1996

Modulation of nuclear receptor interactions by ligands: kinetic analysis using surface plasmon resonance.

Many nuclear hormone receptors, including the human 1,25-dihydroxyvitamin D3 receptor (VDR), bind cooperatively to DNA as either homodimers or heterodimers with the 9-cis-retinoic acid receptor (RXR). Protein-protein interactions mediated by residues within both the DNA- and ligand-binding domains contribute to this binding. We have previously reported that the ligands for VDR and RXR can modulate the affinity of the receptors' interaction with DNA [Cheskis, B., & Freedman, L. P. (1994) Mol. Cell. Biol. 14, 3329-3338]. To examine this in more detail, we report here the use of surface plasmon resonance (SPR) to characterize the kinetics of both protein-protein and protein-DNA interactions by VDR and RXR in the presence and absence of their cognate ligands. We find that 1,25 dihydroxyvitamin D3 binding favors both VDR-RXR heterodimerization and, as a result, DNA binding by the complex. Conversely, the ligand reduces VDR homodimerization in solution and the affinity of VDR-DNA interaction. 9-cis-Retinoic acid attenuates the stimulating effect of 1,25-dihydroxyvitamin D3 by decreasing the rate of VDR-RXR heterodimer formation and simultaneously by increasing the affinity of RXR homodimerization. Thus, using SPR, we have shown that a major role for such ligands is to regulate nuclear receptor dimerization both in solution and on DNA. The ligands appear to do so dynamically, modulating the overall affinity of these complexes. This mechanism therefore creates a fast and sensitive way to regulate DNA binding in response to changes in ligand concentration.

Binding, Competitive↗

PubMed1996

Enzyme inhibition in open systems. Superiority of uncompetitive agents.

Investigations of the open system behavior of reversible dead-end inhibitors were carried out by means of computer simulations and experimental studies. The results from both approaches indicate that substrate-competitive inhibition may often be an inappropriate basis for design of potential therapeutic agents. The use of uncompetitive (also called anticompetitive) inhibitors in this role is likely to be far more effective. Chemical analogs of pathogen-specific enzymic reaction products rather than analogs of substrates provide a promising basis for the systematic design of such uncompetitive inhibitors.

Binding, Competitive↗